These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 38796186)
21. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis. Hong Y; Li X; Wan B; Li N; Chen Y Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906 [TBL] [Abstract][Full Text] [Related]
24. Activity of eltrombopag in severe aplastic anemia. Scheinberg P Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070 [TBL] [Abstract][Full Text] [Related]
25. Eltrombopag: a review of its use in patients with severe aplastic anaemia. McCormack PL Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916 [TBL] [Abstract][Full Text] [Related]
26. Clinical and morphological predictors of outcome in older aplastic anemia patients treated with eltrombopag. Fattizzo B; Kulasekararaj AG; Hill A; Benson-Quarm N; Griffin M; Munir T; Arnold L; Riley K; Ireland R; De Lavallade H; Potter V; Consonni D; Hillmen P; Mufti GJ; Barcellini W; Marsh JCW Haematologica; 2019 Nov; 104(11):e494-e496. PubMed ID: 30890599 [No Abstract] [Full Text] [Related]
27. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia]. Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814 [No Abstract] [Full Text] [Related]
28. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Lengline E; Drenou B; Peterlin P; Tournilhac O; Abraham J; Berceanu A; Dupriez B; Guillerm G; Raffoux E; de Fontbrune FS; Ades L; Balsat M; Chaoui D; Coppo P; Corm S; Leblanc T; Maillard N; Terriou L; Socié G; de Latour RP Haematologica; 2018 Feb; 103(2):212-220. PubMed ID: 29170252 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of eltrombopag in the first-line therapy of severe aplastic anemia in children. Jie M; Fu L; Li S; He Y; Yao J; Cheng X; Zhang L; Zheng J; Zhang R; Wu R Pediatr Hematol Oncol; 2021 Oct; 38(7):647-657. PubMed ID: 33798022 [TBL] [Abstract][Full Text] [Related]
30. Role of eltrombopag in severe aplastic anemia treatment in children. Su MY; Chang HH; Chou SW; Lu MY; Yang YL; Lin DT; Lin KH; Jou ST Pediatr Neonatol; 2021 Nov; 62(6):655-657. PubMed ID: 34420905 [No Abstract] [Full Text] [Related]
31. Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series. Martynova A; Chiu V; Mert M; Hermel D; Weitz IC Ann Hematol; 2021 Apr; 100(4):933-939. PubMed ID: 33420879 [TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of immunosuppressive therapy with or without eltrombopag in pediatric patients with acquired aplastic anemia: A Chinese retrospective study. Fang M; Song H; Zhang J; Li S; Shen D; Tang Y Pediatr Hematol Oncol; 2021 Oct; 38(7):633-646. PubMed ID: 33724146 [TBL] [Abstract][Full Text] [Related]
33. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting. Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047 [TBL] [Abstract][Full Text] [Related]
34. Eltrombopag in children with severe aplastic anemia. Lesmana H; Jacobs T; Boals M; Gray N; Lewis S; Ding J; Kang G; Hale M; Weiss M; Reiss U; Wang W; Wlodarski M Pediatr Blood Cancer; 2021 Aug; 68(8):e29066. PubMed ID: 33855784 [TBL] [Abstract][Full Text] [Related]
35. A promising new treatment for refractory aplastic anemia. Metcalf D N Engl J Med; 2012 Jul; 367(1):74-5. PubMed ID: 22762322 [No Abstract] [Full Text] [Related]
36. [Efficacy and safety of eltrombopag in aplastic anemia: A multi-center survey in China]. Yang WR; Han B; Chang H; Wu BY; Meng FK; Ji DX; Li YM; Zheng ZJ; Fei Y; Shen JP; Hu P; Ding XQ; Zhang P; Wang YQ; Zhang FK Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):890-895. PubMed ID: 33333690 [No Abstract] [Full Text] [Related]
37. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Patel BA; Groarke EM; Lotter J; Shalhoub R; Gutierrez-Rodrigues F; Rios O; Quinones Raffo D; Wu CO; Young NS Blood; 2022 Jan; 139(1):34-43. PubMed ID: 34525188 [TBL] [Abstract][Full Text] [Related]
38. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy. Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813 [TBL] [Abstract][Full Text] [Related]